Licensing agreements for innovator GLP1R drugs weigh in with over $6.2bn in 2024
Innovator drugs targeting glucagon-like peptide-1 receptor (GLP1R) witnessed a 595% increase in total licensing agreement deal value from 2019 to…
Innovator drugs targeting glucagon-like peptide-1 receptor (GLP1R) witnessed a 595% increase in total licensing agreement deal value from 2019 to…